CHLORAPREP TRIPLE SWABSTICK Drug Patent Profile

Which patents cover Chloraprep Triple Swabstick, and what generic alternatives are available?

Chloraprep Triple Swabstick is a drug marketed by Becton Dickinson Co and is included in one NDA.

The generic ingredient in CHLORAPREP TRIPLE SWABSTICK is chlorhexidine gluconate; isopropyl alcohol. There are fifty-eight drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the chlorhexidine gluconate; isopropyl alcohol profile page.

Summary for CHLORAPREP TRIPLE SWABSTICK

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for CHLORAPREP TRIPLE SWABSTICK

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Becton Dickinson Co	CHLORAPREP TRIPLE SWABSTICK	chlorhexidine gluconate; isopropyl alcohol	SWAB;TOPICAL	021555-003	Jun 10, 2009		OTC	Yes	Yes

International Patents for CHLORAPREP TRIPLE SWABSTICK

See the table below for patents covering CHLORAPREP TRIPLE SWABSTICK around the world.

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2200532	DOSAGE APPLICATOR OF BACTERICIDAL SUBSTANCE AND METHOD FOR ITS MANUFACTURING
European Patent Office	0929296	APPLICATEUR UNI-DOSE DE GLUCONATE DE CHLORHEXADINE (GCH) A DUREE DE CONSERVATION PROLONGEE (UNIT DOSE CHLORHEXADINE GLUCONATE (CHG) APPLICATOR HAVING EXTENDED CHG SHELF LIFE)
Brazil	9712117
Japan	2000507478
World Intellectual Property Organization (WIPO)	9814178
China	1231602

Investment Scenario and Fundamentals Analysis for CHLORAPREP TRIPLE SWABSTICK

Last updated: February 22, 2026

What is the product?

CHLORAPREP TRIPLE SWABSTICK is an antiseptic product containing chlorhexidine gluconate, used for preoperative skin preparation and antisepsis. It is designed to reduce microbial load at surgical sites, minimizing infection risk.

Market Overview

The global surgical antiseptics market is projected to grow at a compound annual growth rate (CAGR) of approximately 3.5% from 2022 to 2027, driven by increasing surgical procedures, rising infection control awareness, and expanding healthcare infrastructure in emerging markets.

Patent Landscape

The core patent relating to chlorhexidine-based skin antiseptics has largely expired, with dominant patents in the early 2000s. However, companies have secured patents around specific delivery systems, including swabsticks, formulations, and application methods.

Key patent considerations:

• Expiration dates of core patents: ~2010-2015.
• Secondary patents on delivery devices or formulations: Valid through 2025-2030.
• Geographical patent life: Varies; U.S. patents expire 20 years from filing, often around 2025 for recent filings.

Competitive Positioning

Major players include 3M, Sage Products (a Cardinal Health subsidiary), and local manufacturers. Market entry barriers involve:

• Regulatory approval processes (e.g., FDA clearance).
• Established manufacturing standards.
• Distribution networks.

The presence of multiple patent shields around delivery devices limits immediate generic competition until patent expirations.

Regulatory & Reimbursement Environment

The product falls under medical device and antiseptic drug categories. Regulatory approvals hinge on demonstrating safety, efficacy, and manufacturing quality. Reimbursement policies for surgical antiseptics are generally favorable, with coverage integrated into hospital infection control protocols.

Commercialization & Growth Drivers

Growth drivers for CHLORAPREP TRIPLE SWABSTICK include:

• Increased surgical volumes, especially in orthopedics, cardiology, and general surgery.
• Protocol standardization favoring antiseptic application techniques.
• Rising healthcare expenditure and focus on infection control.

Potential barriers:

• Generic competition post-patent expiry.
• Market saturation in mature regions.
• Price sensitivity in hospital procurement.

Investment Risks

• Patent cliffs after 2025 could lead to commoditization.
• Regulatory delays or restrictions.
• Competitive development of enhanced antiseptics or novel application methods.
• Supply chain disruptions impacting production and distribution.

Financial Fundamentals

No specific financial data exist publicly for CHLORAPREP TRIPLE SWABSTICK as a standalone product. However, the segment's financial viability includes:

• Moderate gross margins (~40-60%) for antiseptic products.
• R&D expenses primarily for formulation improvements and device innovations.
• Marketing costs driven by hospital and healthcare provider sales channels.

Valuation Metrics and Market Potential

Assuming moderate market penetration and growth, revenue estimates for the US antiseptic swabstick segment could reach $300 million annually by 2030 for top players, with potential for product line extensions and patent-driven sales increases.

Strategic Implications

Investors should consider:

• Monitoring patent expiry timelines.
• Evaluating R&D pipelines for innovative antiseptic delivery systems.
• Analyzing regional regulatory developments impacting product approval.
• Assessing competitive dynamics, including potential generics entering post-patent expiration.

Key Takeaways

• CHLORAPREP TRIPLE SWABSTICK operates in a mature, stable segment with consistent demand.
• Patent expirations around 2025-2030 pose significant upside risk.
• Market growth depends on surgical volume increases and infection control policies.
• Competitive advantage relies on device innovation and regulatory approval status.

FAQs

Q1: When will patent expiry typically occur for the core chlorhexidine formulations?
A: Around 2010-2015, though secondary patents on devices or formulations might extend protection to 2025-2030.

Q2: What are the main competitive threats?
A: Patent expiration leading to generics, development of superior antiseptics or application methods, and price competition.

Q3: How does regulatory approval impact investment prospects?
A: Delays or restrictions can hinder market access, reducing revenue potential. Conversely, favorable policies can accelerate growth.

Q4: What is the primary growth driver for this product?
A: Increasing surgical procedures worldwide and standard infection control protocols.

Q5: Are there any recent innovations in antiseptic swabstick technology?
A: Companies are investing in device design improvements and formulation enhancements, which may extend market exclusivity.

---

References

1. MarketsandMarkets. (2022). Surgical antiseptics market forecast.
2. U.S. Patent and Trademark Office. (2023). Patent expiration timelines.
3. IMS Health. (2021). Hospital infection prevention market analysis.
4. FDA. (2022). Regulatory guidelines for antiseptic products.
5. Deloitte. (2022). Healthcare innovation and patent strategies.